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Abstract: The main protease (Mpro) of the newly emerged severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) was subjected to hyphenated pharmacophoric-based and structural-
based virtual screenings using a library of microbial natural products (>24,000 compounds). 
Subsequent filtering of the resulted hits according to the Lipinski’s rules was applied to select only 
the drug-like molecules. Top-scoring hits were further filtered out depending on their ability to 
show constant good binding affinities towards the molecular dynamic simulation (MDS)-derived 
enzyme’s conformers. Final MDS experiments were performed on the ligand–protein complexes 
(compounds 1–12, Table S1) to verify their binding modes and calculate their binding free energy. 
Consequently, a final selection of six compounds (1–6) was proposed to possess high potential as 
anti-SARS-CoV-2 drug candidates. Our study provides insight into the role of the Mpro structural 
flexibility during interactions with the possible inhibitors and sheds light on the structure-based 
design of anti-coronavirus disease 2019 (COVID-19) therapeutics targeting SARS-CoV-2. 
Keywords: SARS-CoV-2; Covid-19; Mpro; microbial natural products; docking; molecular dynamic 
simulation 
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1. Introduction 
In 2002, the first spread of coronavirus associated with severe acute respiratory syndrome 
coronavirus (SARS-CoV) emerged in southern China. This outbreak successfully subsided by the 
summer of 2003 [1], with no more than 8500 confirmed infections and just over 900 deaths worldwide 
[2]. Upon the spread of this outbreak, the global response was immediate to characterize its causative 
agent as a novel coronavirus (SARS-CoV) [3]. The recurrence of SARS in the Guangdong province of 
China in December 2003 [4] illustrated the need to continue efforts to study this virus and its key 
molecular targets to develop appropriate therapeutics for its treatment. In 2012, another coronavirus 
wave originating in Jeddah, Saudi Arabia emerged and spread within and beyond the Middle East. 
The reported strain (MERS-CoV) was associated with severe pneumonia and multi-organ failure [5]. 
The limited number of infected cases during the previous coronaviruses waves did not encourage a 
serious worldwide development of effective treatments. 
Recently and until June 2020, the outbreak of a new coronavirus (SARS-CoV-2) that originated 
from Wuhan, China, in late 2019, has led to more than 9.3 million infections and more than 479,000 
deaths throughout 216 countries without any proven antiviral agents or effective vaccine according 
to WHO official updates. However, repurposing of previous medications has shown some reported 
clinical improvements [6]. This time, worldwide efforts are being made to characterize molecular 
targets, pivotal for the development of anti-coronavirus therapies. The term coronavirus was coined 
according to its corona-like appearance in the electron microscope, due to its spikes that radiate 
outwards from the viral envelope. The spherical capsid envelops a positive-strand RNA genome of 
about 30 kb, which is considered the largest of its kind. The viral genome is predominated by two 
open reading frames that are connected by a ribosomal frameshift site and encode the two replicase 
proteins, pp1a and pp1ab [7]. These polyproteins are cleaved by the viral main protease (Mpro), also 
called chymotrypsin-like protease, 3CLPro [8,9]. Mpro is considered a highly conserved molecular 
target across coronaviruses, and hence, it was designated as a potential target for anti-coronavirus 
drug development [10]. Earlier reports on viral protease inhibitors (i.e., the HIV protease inhibitor 
lopinavir) revealed significant in vitro anti-SARS-CoV-2 activities [11]. 
Natural products along with natural product-inspired synthetic and semisynthetic compounds 
are still an excellent structural motif for the discovery of new therapeutics, including antiviral agents. 
Natural products derived from microbial sources are considered unique in their chemical diversity 
in comparison with plant-derived ones. Approximately 53% of the FDA-approved natural products-
based drugs are of microbial origin, notably the antiviral ones [12]. For example, Ara-A (9) (also 
known as vidarabine) is considered one of the earliest antiviral nucleoside analogues that was 
reported from Streptomyces antibioticus [13]. Afterwards, several nucleoside-based antiviral agents of 
microbial origin were developed [14]. Additionally, several ansamycins-based antibiotics (e.g., 
rifamycin, 10) have shown interesting antiviral properties against a wide range of infectious viruses 
[15]. Furthermore, the well-known immunomodulatory drug of fungal origin mycophenolic acid (11) 
has also shown a broad antiviral activity [15] 
Recently, the microbial-derived FDA-approved anti-parasitic drug ivermectin (12), a 
semisynthetic pentacyclic sixteen-membered lactone derived from the soil bacterium Streptomyces 
avermitilis, proved to be an effective in vitro inhibitor of SARS-CoV-2 replication [16,17]. In this 
context, several in silico techniques that have recently gained a lot of attention in drug discovery 
campaigns (e.g., structure and ligand-based virtual screening, docking and molecular dynamics) 
[18,19]. Hence, we initiated a virtual screening of a big library of microbial natural products (more 
than 24,000 compounds) aimed at the discovery of potential drug candidates against the SARS-CoV-
2 Mpro, taking into account the drug-likeness properties to select only druggable candidates. Simple 
docking protocols do not take into consideration the flexible nature of proteins; therefore, their 
success rates in most cases are between 60–70% [20]. To increase the docking performance, top hits 
retrieved from the primary pharmacophore-based screening were further docked on a series of 
receptor conformers (i.e., ensemble docking) [21] taken from the molecular dynamic simulation 
(MDS) to consider the factor of the binding pockets’ flexibility. Finally, further MDS of the protein–
ligand complexes were performed to verify our docking experiments and calculate their binding free 
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energy (ΔG). Drug candidates proposed in this study could provide a promising starting point for 
the in vitro and in vivo testing and further development of potential drug leads against the newly 
emerged coronavirus disease 2019 (COVID-19). The procedure of the current investigation is 
depicted in Figure 1. 
 
Figure 1. Applied strategy in the present study. 
2. Materials and Methods 
2.1. Preparation of SARS-CoV-2 Mpro and the Compounds Dataset 
Crystal structures of Mpro (PDB code: 6LU7 and 6M2N) were obtained from the Protein Data 
Bank (http://www.pdb.org), and all heteroatoms and water molecules were removed for MDS and 
molecular docking studies. The chemical structures of the tested microbial specialized metabolites 
were retrieved from the online dataset; The Natural Products Atlas 
(https://www.npatlas.org/joomla/index.php) [22] with a final compiled dataset consisting of 24,581 
compounds. Subsequently, this library of compounds was subjected to LigandScout software [23] to 
select 9933 compounds that showed drug-like properties (i.e., obey Lipinski’s role of five) [24]. 
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2.2. Molecular Dynamic Simulation 
Molecular dynamic simulations (MDS) for the free Mpro enzyme and ligand–enzyme complexes 
were performed using the Nanoscale Molecular Dynamics (NAMD) 2.6 software [25], employing the 
CHARMM27 force field [26]. Hydrogen atoms were added to initial coordinates for Mpro using the 
psfgen plugin included in the Visual Molecular Dynamic (VMD) 1.9 software [27]. Subsequently, the 
protein system was solvated using TIP3P water particles and 0.15 M NaCl. The equilibration 
procedure comprised 1500 minimization steps followed by 30 ps of MDS at 10 k with fixed protein 
atoms. Then, the entire system was minimized over 1500 steps at 0 K, followed by gradual heating 
from 10 to 310 K using temperature reassignment during the initial 60 ps of the 100 ps equilibration 
MDS. The final step involved NTP simulation (30 ps) using the Nose–Hoover Langevin piston 
pressure control at 310 K and 1.01325 bars for density (volume) fitting [28]. Thereafter, the MDS was 
continued for 25 ns for the entire system (20 ns for the enzyme–ligand complexes). The trajectory was 
stored every 0.1 ns and further analyzed with the VMD 1.9 software. The MDS output over 25 ns 
provided several structural conformers that were sampled every 0.1 ns to evaluate the conformational 
changes of the entire protein structure to analyze the root mean square deviation (RMSD) and root 
mean square fluctuation (RMSF). All parameters and topologies of the compounds selected for MDS 
(1–12, Table S1) were prepared using the online software Ligand Reader & Modeler 
(http://www.charmm-gui.org/?doc=input/ligandrm) [29] and the VMD Force Field Toolkit (ffTK) 
[27]. Binding free energy calculations (ΔG) were performed using the free energy perturbation (FEB) 
method through the web-based software Absolute Ligand Binder [30] together with the MDS 
software NAMD 2.6 [25]. Additionally, they were calculated using another web-based software, 
namely KDEEP (https://www.playmolecule.org/Kdeep/), which applies a neural-networking algorithm 
during its computations [31]. 
2.3. Pharmacophore-Based Virtual Screening and Molecular Docking 
The pharmacophore-based screening was performed by the online sever Pharmit 
(http://pharmit.csb.pitt.edu/) [32]. The pharmacophore models were constructed from the SARS-Mpro 
enzymes co-crystallized with baicalein (7) and N3 (8). All the pre-installed Pharmit parameters 
remained unchanged. The resulting two models were used for the virtual screening of the 
compounds filtered from the prepared microbial natural products library (9933 compounds). 
Afterwards, compounds with RMSD >2Å were excluded. Docking experiments were performed 
using AutoDock Vina software [33]. All compounds that fitted into the predetermined 
pharmacophore models (57 compounds) were then subjected to molecular docking against the Mpro’s 
active site conformers that were sampled from the MDS every 5 ns (i.e., ensemble docking). We set 
an average docking score of −10 kcal/mol (the average docking score of compound 7) as a cut-off to 
select the top-scoring hits. Afterwards, the retrieved top hits (1–12, Table S1) were ranked according 
to their binding energies (Table 1 and Table S1). The generated docking poses were visualized and 
analyzed using Pymol software [34].
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Table 1. Mpro top-scoring ligands alongside their binding energies using different calculation methods and their molecular interactions inside the active site. 
Ligand ΔGVina 
(kcal/mol) 
ΔG*FEP 
(kcal/mol) 
ΔG**KDEEP 
(kcal/mol) 
ΔGaverage 
(kcal/mol) 
Hydrogen Bonding 
Interactions Hydrophobic Interactions 
Citriquinochroman (1) −14.7 −11.9 −10.5 −12.4 
THR-26, ASN-142, GLY-143, 
CYS-145, GLU-166, ASP-187, 
ARG-188, GLN-189, THR-
190, GLN-192 
HID-41, MET-49, PRO-168 
Holyrine B (2) −14.5 −11.5 −10.9 −12.3 
LEU-141, ASN-142, GLY-143, 
SER-144, CYS-145, HID-163, 
HIE-164, GLU-166, PRO-168, 
ASP-187, ARG-188, GLN-189, 
THR-190, GLN-192 
HID-41, MET-49, MET-165, 
PRO-168 
Proximicin C (3) −14.1 −12.1 −10.3 −12.2 
GLY-143, SER-144, CYS-145, 
GLU-166, PRO-168, ASP-187, 
ARG-188, GLN-189, THR-190 
Leu-27, HID-41, MET-49, 
MET-165, PRO-168 
Pityriacitrin B (4) −13.4 −12.1 −11.1 −12.2 
PHE-140, LEU-141, GLY-143, 
SER-144, CYS-145, HID-163, 
HIE-164, MET-165, GLU-166, 
GLN-189 
HID-41, MET-49, GLN-189 
Anthrabenzoxocinone (5) −13.2 −10.3 −9.5 −11 
THR-26, HID-41, CYS-44, 
ASN-142, GLY-143, CYS-145, 
HIE-164, HIE-164, MET-165, 
GLU-166, VAL-186, ASP-187, 
ARG-188, GLN-189, THR-
190, GLN-192 
HID-41, MET-49, MET-165, 
GLN-189 
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Penimethavone A (6) −12.1 −11.4 −8.9 −10.8 
LEU-141, GLY-143, SER-144, 
CYS-145, HIE-164, HIE-164, 
MET-165, GLU-166, HID-172, 
VAL-186, ASP-187, ARG-188, 
GLN-189, GLN-192 
HID-41, MET-49, MET-165, 
GLN-189 
Co-crystalized ligand (7) −10.1 −9.2 −8.9 −9.4 
LEU-141, ASN-142, GLY-143, 
GLU-166, GLN-189. HID-41, MET-49, GLN-189 
Co-crystalized ligand (8) −10.9 −11.4 −9.4 −10.6 
PHE-140, GLY-143, CYS-145, 
HIE-164, GLU-166, GLN-189, 
THR-190. 
HID-41, MET-49, GLN-189 
*Binding free energy calculated by the free energy perturbation (FEB) method [30], **Binding free energy calculated by a neural networking method (KDEEP) [31]. 
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3. Results and Discussion 
3.1. Structure and Dynamics of the SARS-CoV-2 Mpro 
The catalytic site of the SARS-CoV-2 Mpro was found to be the largest cavity on the whole protein 
(static volume = 385.56 Å3) and is located in domains I and II (residues 11 to 99 and 100 to 182, 
respectively, Figure 2A). Additionally, it is smaller than the earlier SARS-CoV Mpro (static volume = 
447.7 Å3) [35]. It is worth noting that the enzyme’s domain III, which consists of a globular cluster of 
five helices, is present only in coronaviruses and is responsible for the regulation of Mpro dimerization 
[36]. MDS of the reported SARS-CoV-2 Mpro (PDB: 6LU7) [10] was performed to study the 
conformational changes in the active site using clustering analysis (conformation was sampled every 
0.1 ns). The carbon alpha (Cα) root main square deviation (RMSD) values with respect to the initial 
structure were calculated for 25 ns of the simulation and were found to oscillate from 0.78 to 2.78 Å 
with a median value of (2.51 Å), reaching equilibrium (i.e., plateau) at 4.8 ns (Figure 2D). Regarding 
root mean square fluctuation (RMSF) values, they demonstrated that Mpro had moderate flexibility 
(average RMSF = 2.43 Å, Figure 2E), where the active site showed the highest conformational changes 
(average RMSF = 3.1 Å), particularly at the THR-45 to ILE-59 loop (Figure 2B), which showed high 
fluctuations (i.e., RMSF values ranged from 5.2 to 8.9 Å, Figure 2E). 
The volume of the active site was 399.56 Å3 at the beginning of the simulation (Figure 2C), and 
during the MDS, it gradually increased to reach 479.65 Å3 at 10 ns, and then began to decrease to 
reach 314.63 Å3 at the end of the MDS. Docking and virtual screening studies on such flexible catalytic 
active sites using only their crystalized static form would lead to poor prediction results. Hence, 
considering multiple structural conformations (i.e., ensemble docking) derived from the MDS study 
for our virtual screening in the present investigation could significantly improve the predicted 
results. 
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Figure 2. (A): The main domains (Mpro) in severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) (Brick red: Domain I, Golden yellow: Domain II, Cyan: Domain III), (B): Heat-map illustrating 
the flexible regions on SARS-CoV-2 Mpro , (C): The active site volume changes during the course of 
molecular dynamic simulation (MDS) (D and E): root main square deviation (RMSD) and root main 
square fluctuation (RMSF) of SARS-CoV-2 Mpro after 25 ns of MDS. 
3.2. Pharmacophore-Based Modeling and Screening 
To discover potential naturally occurring ligands that could block the Mpro active site, an 
extensive specialized microbial natural product database (The Natural Product Atlas) containing 
more than 24,000 different compounds was utilized for. Firstly, the database was filtered according 
to drug-likeness (Lipinski’s rules [24]) to get 9933 drug-like candidates. 
The crystal structure of SARS-CoV-2 Mpro (PDB id: 6LU7) was reported earlier, along with its co-
crystallized peptide inhibitor N3 [10]. N3 (8) is fitted inside the Mpro active site through multiple 
strong H-bonds (e.g., GLY-143, HIS-164, GLU-166, GLN-189, and THR-190) alongside a covalent 
bond with CYS-145. Additionally, its isopropyl group is imbedded inside a hydrophobic pocket that 
consists of HIS-41, MET-49, and GLN-189 (Figure 3A, Table 1). 
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Recently, a novel flavonoid-based non-covalent inhibitor (baicalein, 7) (PDB code: 6M2N) was 
found to accept seven H-bonds from LEU-141, ASN-142, GLY-143, Glu-166, and GLN-189. Moreover, 
its phenyl moiety was also fitted inside the hydrophobic pocket of HIS-41, MET-49, and GLN-189 
(Figure 3C, Table 1). The predetermination of pharmacophoric characteristics prior to structure-based 
virtual screening would help in selecting the best hits with the best interaction inside the binding 
pocket [37]. 
To define the essential features of the interaction inside the Mpro’s active site [32], two structure-
based pharmacophore models were constructed depending on the two previously described 
inhibitors. The N3 (8)-based-pharmacophore model had the following features: four H-bond donors 
derived from four amide groups, one carboxyl group-derived oxygen atom as an H-bond acceptor, 
and the isopropyl group to represent a hydrophobic center (Figure 3B). On the other hand, the 
baicalein (7)-based pharmacophore model showed the following features: two H-bond acceptors 
derived from one hydroxyl group and the ketonic oxygen, one H-bond donor derived from another 
hydroxyl group, and the phenyl group to represent a hydrophobic center (Figure 3D). 
Subsequently, these binding site-derived pharmacophore models were used in our virtual 
screening against the MND-selected compounds (the 9933 compounds that obey Lipinski’s rules) 
using the online server Pharmit [32]. This allowed us to select the compounds with predetermined 
pharmacophoric features capable of interacting with the reported key residues. This filtration step 
led to the recognition of 363 compounds that met the predetermined model features, of which we 
selected only 57 compounds (i.e., showed RMSD values lower than 2 Å with respect to the co-
crystalized ligands 7 and 8) to undergo a subsequent docking-based virtual screening. 
 
Figure 3. Generated pharmacophore models (B and D) according to the previously reported co-
crystalized ligands (7 and 8, A and C). Gray spheres indicate hydrogen bond donors, orange spheres 
indicate hydrogen bond acceptors, and green spheres indicate hydrophobic centers. Green amino acid 
residues represent the S1 pocket, blue amino acid residues represent the S2 pocket, yellow amino acid 
residues represent the S3 and S4 pockets in the Mpro active site (A and C). 
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3.3. Molecular Docking and Binding Mode Investigation 
Docking of the selected compounds inside the Mpro active site was performed on AutoDock Vina, 
which was able to reproduce the binding mode of the co-crystalized ligands [37], N3 (8) and baicalein 
(7), with an RMSD values of 1.22 and 0.51 Å, respectively. Fifty seven compounds were filtered 
according to the predetermined pharmacophoric features and drug-likeness properties, and 
thereafter docked separately on the SARS-CoV-2 Mpro active site using several snapshots (every 5 ns) 
derived from the MDS (i.e., ensemble docking). This allowed us to further select the best binding 
compounds taking into consideration the flexibility of the active site. Top-scoring hits (those with an 
average binding energy score > −10 kcal/mol, Table S1 and Figure S1) with binding modes comparable 
with both N3 (8) and baicalein (7), were then subjected to MDS and binding free energy computation 
to further verify the suggested pharmacophore models, docking-derived binding poses, and binding 
affinities. Only compounds 1–6 (Figure 4 and Table 1) exhibited stable binding orientations inside the 
enzyme binding pocket throughout the MDS (Figures S2–S13) and constant binding energies higher 
than that of the co-crystallized inhibitors, i.e., compounds 7 and 8. 
 
Figure 4. Top-scoring compounds (1–6) retrieved from the in silico virtual screening on the Mpro active 
site along with the co-crystallized inhibitors 7 and 8 in addition to the previously reported antiviral 
microbial natural products (9–12). 
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Our Mpro top-scoring ligands indicated that the best hit was citriquinochroman (1). This N-
containing polyketide was first isolated from the endophytic fungus Penicillium citrinum in 2013 and 
showed moderate anticancer activity [38]. It showed the least binding energy (ΔG average = −12.4 kcal/ 
mol), with perfect fitting inside the enzyme active site in the crystallized form, where it anchored 
itself via a network of H-bond interactions with the reported key binding residues (7 H-bonds) [10]. 
Despite the flexibility of the enzyme active site, citriquinochroman (1) was able to keep its orientation 
during the course of MDS (Figure 5 and S2) with a transient drop in its binding affinity at 3–5.5 ns 
(ΔG Vina = −8.9 kcal/mol). Afterwards, both THR-26 and GLN-192 stabilized compound 1 with 
additional H-bond interactions until the end of the MDS (Figure 5). 
The second most promising hit was holyrine B (2), an indolocarbazole alkaloid that was 
previously isolated from a marine-derived actinomycete [39]. Holyrine B (2) exhibited binding modes 
similar to that of citriquinochroman (1), where it also interacted through H-bonding or hydrophobic 
interactions with the reported key amino acid residues [10]. Additionally, it was able to keep these 
strong interactions throughout the MDS and form additional H-bonds and hydrophobic interactions 
with extra amino acid residues like HID-163, HIE-164, PRO-168, and MET-165 (Figure 5 and Table 1). 
The third best hit was the aminofuran antibiotic proximicin C (3), which was isolated from the 
marine actinomycete Verrucosispora MG-37 [40]. Proximicin C (3) showed an interesting binding pose 
inside the enzyme active site in the crystalized form where it interacted with several amino acid 
residues including the reported ones (9 H-bonds and 2 hydrophobic interactions, Figure 6). During 
the MDS and in contrast to the previous candidates (1 and 2), proximicin C’s (3) binding affinity 
remained constant for 5 ns and started to increase afterwards until the end of the simulation. Such 
stable fitting inside the binding site could be attributed to the molecular flexibility of this compound 
that enabled it to accommodate itself well inside the changing active site of SARS-CoV-2 Mpro (Figure 
6). 
Pityriacitrin B (4) showed excellent fitting inside the Mpro active site, where the phenyl moiety of 
the β-carboline part was impeded inside the hydrophobic pocket (HID-41, MET-94, GLN-189), while 
the other indole arm together with the β-carboline’s pyridine moiety interacted with the key binding 
amino acid residues (PHE-140, LEU-141, GLY-143, and GLU-166, Figure 6). Moreover, it was able to 
not only keep these interactions throughout the MDS, but also to form additional strong H-bonds 
with THR-26, SER-144, and CYS-145. Pityriacitrin B (4) was first isolated from the human pathogenic 
yeast Malassezia furfur [41]. Later on, it was identified as an efficient UV absorbing agent [42]. 
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Figure 5. Interactions and binding modes of compounds 1 and 2 (Blue and red molecules, 
respectively) inside the Mpro active site in the crystal form and during MDS (1-A–2-F). 
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Figure 6. Interactions and binding modes of compounds 3 and 4 (Blue and red molecules, 
respectively) inside the Mpro active site in the crystal form and during MDS (3-A–4-F). 
Coming to our next hit, (+)-anthrabenzoxocinone (5), it showed an interaction pattern similar to 
the previous candidates (1–4, and 7, 8) inside the crystallized form of the enzyme active site. 
However, from the beginning of the MDS, this compound gradually detached itself from the binding 
site, and starting from 7.2 ns, it took a different orientation with better interactions (Figure 7 and 
Table 1). At the end of the MDS, (+)-anthrabenzoxocinone (5) was able to form a wide network of H-
bonds (10 H-bonds) and hydrophobic interactions (4 hydrophobic interactions) (Figure 7). 
Anthrabenzoxocinone (5) was isolated from a soil-derived Streptomyces sp. in 2014 [43]. 
Finally, penimethavone A (6), which has a flavone structure similar to the co-crystalized ligand 
(baicalein, 7), was able to form molecular interactions almost identical to those of the co-crystalized 
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ligand (7) (Figure 3C, 7 and Table 1). Additionally, it adopted a stable binding mode during the MDS, 
particularly near the end of simulation when it expanded its H-bonds network to involve extra 
binding residues like HIE-164 and HID-172. Penimethavone A (6) is an unusual flavone derivative 
with a methylated B-ring that was isolated from the gorgonian marine soft coral-derived Penicillium 
chrysogenum [44]. 
 
Figure 7. Interactions and binding modes of compounds 5 and 6 (Blue and red molecules, 
respectively) inside the Mpro active site in the crystal form and during MDS (5-A–6-F). 
4. Conclusions 
The SARS-CoV-2 pandemic crisis has inspired scientists with diverse backgrounds to help with 
a speedy discovery of potential treatments or vaccines. In the present virtual screening and molecular 
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modelling study, we suggested that the active site of the newly emerged SARS-CoV-2 Mpro is quite 
flexible. Thus, its utilization in just simple docking experiments could lead to inaccurate results. 
Consequently, this catalytic active site was utilized in a combination of ligand-based followed by 
structural-based virtual screening against a big library of microbial-derived specialized metabolites, 
which was initially filtered according to the drug-likeness of its molecules. Top-scoring hits were 
further subjected to an ensemble docking protocol depending on the enzyme-generated conformers 
during the MDS. This step allowed us to select only ligands with stable binding affinity and modes 
for considering the flexibility of the active binding site. MDS, together with binding energy and 
affinity computations were performed for the selected hits as a final validation step to nominate six 
molecules with possible high potential to modulate/inhibit the SARS-CoV-2 Mpro active site. This 
study emphasized the power of computer-aided drug design and modelling in speeding up the 
process of drug discovery, which is currently an urgent need under the spread of COVID-19. It also 
highlighted the ability of natural products, particularly those of high structural diversity like 
microbial-derived metabolites, to provide potential drug-leads. Further in vitro testing of the drug 
candidates retrieved from our study is highly recommended as a promising starting point for the 
rapid development of drug leads against newly emerged COVID-19. 
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scoring hits retrieved from the structural-based virtual screening. 
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